KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Q3 2025 value amounting to -$641000.0.

  • Aurinia Pharmaceuticals' Change in Accured Expenses fell 9191.62% to -$641000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$308000.0, marking a year-over-year increase of 9188.83%. This contributed to the annual value of $13.3 million for FY2024, which is 967.58% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Change in Accured Expenses stood at -$641000.0, which was down 9191.62% from $6.3 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $17.5 million during Q4 2024, with a 5-year trough of -$23.4 million in Q1 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Change in Accured Expenses value was $462000.0 (recorded in 2022), while the average stood at $698631.6.
  • In the last 5 years, Aurinia Pharmaceuticals' Change in Accured Expenses tumbled by 67560.78% in 2021 and then surged by 593135.59% in 2022.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Change in Accured Expenses stood at $2.9 million in 2021, then tumbled by 78.95% to $616000.0 in 2022, then tumbled by 44.48% to $342000.0 in 2023, then skyrocketed by 5007.89% to $17.5 million in 2024, then tumbled by 103.67% to -$641000.0 in 2025.
  • Its Change in Accured Expenses was -$641000.0 in Q3 2025, compared to $6.3 million in Q2 2025 and -$23.4 million in Q1 2025.